Johns Hopkins Bloomberg School of Public Health
jhsph.eduLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
365
Active
49
Phase 3
40
Total enrollment
1,663,815
Pipeline matrix
Showing 5 of 5 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Artemether-lumefantrine | — | — | — | — | — | 1 | |
| Dihydroartemisinin-piperaquine | — | — | — | — | — | 1 | |
| Nitazoxanide | — | — | — | — | — | 1 | |
| A package of oral health interventions, including a daily antiseptic oral rinse | — | — | — | — | — | 1 | |
| Azithromycin | — | — | — | — | — | 1 |
Next readouts
- 2020-08-24
- 2028-12
- 2028-12-31
- 2029-08
Top conditions
- HIV Infections20
- Obesity20
- HIV18
- Surveys and Questionnaires11
- Depression10
- Anxiety10
- Substance Use10
- Noncommunicable Diseases10
Frequently asked questions about Johns Hopkins Bloomberg School of Public Health
- How many clinical trials does Johns Hopkins Bloomberg School of Public Health have on ClinicalTrials.gov?
- Johns Hopkins Bloomberg School of Public Health is listed as the lead sponsor on 365 clinical trials in ClinicalTrials.gov, 49 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Johns Hopkins Bloomberg School of Public Health's trials are in Phase 3?
- 40 of Johns Hopkins Bloomberg School of Public Health's trials are in Phase 3, spread across 5 active drug programs.
- What therapeutic areas does Johns Hopkins Bloomberg School of Public Health focus on?
- Johns Hopkins Bloomberg School of Public Health's most-studied conditions on ClinicalTrials.gov are HIV Infections, Obesity, HIV, Surveys and Questionnaires, Depression.
- When are Johns Hopkins Bloomberg School of Public Health's next clinical trial readouts?
- Johns Hopkins Bloomberg School of Public Health has 4 upcoming primary-completion readouts tracked here; the soonest is “Pharmacokinetics and Pharmacodynamics of the Gametocytocidal and Post-treatment Chemoprotective Effects of Antimalarials”, expected around 2020-08-24.